No Data
No Data
Collective crossover! These famous fund hold position managers in A-shares have significantly increased their positions in Hong Kong stocks.
Famous funds managing A-share products have begun to taste the performance benefits of cross-border positions, which has led many A-share funds to heavily increase their holdings of Hong Kong stocks.
Goldman Sachs has lowered the target prices for medical-related stocks across the board in 'Dahang'. Investors are still concerned about the impact of anti-corruption measures.
Goldman Sachs released a report and lowered the target prices of medical-related stocks by an average of about 9% ahead of the second quarter and first half performance season. At the same time, the industry sales forecast for fiscal years 2024 to 2025 were lowered by 1% to 15% and 1% to 16%, respectively. The bank believes that investors will continue to pay attention to the potential impact of anti-medical corruption, recent procurement policy updates, and the potential stimulus of trade-in programs. Goldman Sachs' investment ratings and target prices for pharmaceutical stocks are listed as follows: Stock | Investment Rating | Target Price (HKD) Weigao Group (01066.HK) | Buy | 7.8 yuan -> 8.7 yuan Kangji Medical
Hong Kong Stock Market Changes | Hygeia Health (06078) is up more than 4% now, new acquisition of hospital contributes to performance. Nomura expects to achieve record high first-half results.
Hygeia Health (06078) has risen over 4% and as of press time, it rose 3.58% to HK$27.5 with a turnover of HK$17.4431 million.
Nomura Adjusts Hygeia Healthcare's Price Target to HK$50.70 From HK$58.20, Keeps at Buy
Nomura: Maintains a 'buy' rating for Hygeia Health (06078) and lowers the target price to HKD 50.7.
Nomura has lowered its revenue forecasts for Hygeia Health for the next two years by 3.3% and 5.5% respectively.
Nomura reduces Hygeia Health's (06078.HK) target price to HKD 50.7, lowering revenue and profit forecasts.
Nomura released a research report, lowering its revenue forecast for Hygeia Health (06078.HK) by 3.3% and 5.5% for the next two years, and profit forecast by 0.6% and 14.1% respectively. This is lower than the market's general expectations, mainly due to the slower-than-expected operating efficiency and medical capacity improvement speed of newly built and merged hospitals, as well as the expected increase in operating expenses for mergers and integrations. Nomura accordingly lowered Hygeia Health's target price from 58.2 yuan to 50.7 yuan, pointing out that its current price corresponds to a forecast PE of about 17.1 times and 13.7 times for the next two years, which is more attractive, hence maintaining a "buy" rating.
No Data